Bantam Pharmaceutical
Manufacturing · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
505 Park Ave, New York, New York, 10022,...Phone Number
(646) 598-4823Website
www.bantampharma.comRevenue
<$5 MillionIndustry
About Bantam Pharmaceutical
Bantam Pharma is focused on redefining cancer care by developing novel, first-in-class small molecule oral therapeutics aimed at difficult-to-treat hematological and solid tumors. Their lead candidate, BTM-3566, targets cancer cells by restoring apoptosis, showing promising results in preclinical studies, particularly against Diffuse Large B-cell Lymphoma. The company leverages its expertise in mitochondrial dynamics to innovate cancer treatment and is actively seeking partners and investors for clinical development. With a capital-efficient operating model, Bantam Pharma is positioned for aggressive product development in the oncology sector.Explore more
Bantam Pharmaceutical Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Bantam Pharmaceutical
Compare insights from companies similar to Bantam Pharmaceutical, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Bantam Pharmaceutical Tech Stack
A closer look at the technologies used by Bantam Pharmaceutical
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Bantam Pharmaceutical
Sign Up For FreeTo access detailed company insights
Bantam Pharma is focused on redefining cancer care by developing novel, first-in-class small molecule oral therapeutics aimed at difficult-to-treat hematological and solid tumors. Their lead candidate, BTM-3566, targets cancer cells by restoring apoptosis, showing promising results in preclinical studies, particularly against Diffuse Large B-cell L... Read More
